An atypical presentation for primary sclerosing cholangitis

被引:22
作者
Luketic, VAC
Gomez, DA
Sanyal, AJ
Shiffman, ML
机构
[1] Hepatology Section, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
[2] Greenbrier Medical Center, Ronceverte, WV 24970
[3] Hepatology Section, Medical College of Virginia, Richmond, VA 23298
关键词
primary sclerosing cholangitis; autoimmune hepatitis; atypical presentation; cholangiography; corticosteroid therapy;
D O I
10.1023/A:1018845829198
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We describe the clinical course of a group of patients with primary sclerosing cholangitis who at presentation were diagnosed to have autoimmune hepatitis. The history of one such patient is described in detail. We also compare this atypical sclerosing cholangitis (group I) to typical sclerosing cholangitis (group II) and to autoimmune hepatitis with (group III) and without (group IV) cholestasis. At presentation, mean AST in groups I and III was similar and significantly higher than in group II (P < 0.05). Mean ALP was higher in sclerosing cholangitis than in autoimmune hepatitis but not significantly so. Triaditis was present in all patients in groups I, III, and IV. Piecemeal necrosis and multilobular collapse/fibrosis were equally frequent in groups I, III, and IV. Only the response to corticosteroids helped differentiate among groups. Groups III and IV responded by normalizing AST. In group I, AST improved, but never became normal. As ALP became disproportionately abnormal (ALP-predominant pattern), cholangiography was performed, and the diagnosis of primary sclerosing cholangitis was made in all group I patients. We recommend that cholangiography be performed early in patients with suspected autoimmune hepatitis who partially respond to corticosteroids and develop an ALP-predominant pattern.
引用
收藏
页码:2009 / 2016
页数:8
相关论文
共 19 条
[1]   AUTOIMMUNE CHOLANGIOPATHY - PART OF THE SPECTRUM OF AUTOIMMUNE CHRONIC ACTIVE HEPATITIS [J].
BENARI, Z ;
DHILLON, AP ;
SHERLOCK, S .
HEPATOLOGY, 1993, 18 (01) :10-15
[3]   AUTOIMMUNE HEPATITIS - EVOLVING CONCEPTS AND TREATMENT STRATEGIES [J].
CZAJA, AJ .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) :435-456
[4]  
CZAJA AJ, 1984, SEMIN LIVER DIS, V4, P1, DOI 10.1055/s-2008-1040641
[5]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[6]  
DUERR RH, 1991, GASTROENTEROLOGY, V100, P1385
[7]   MEETING REPORT - INTERNATIONAL-AUTOIMMUNE-HEPATITIS-GROUP [J].
JOHNSON, PJ ;
MCFARLANE, IG ;
ALVAREZ, F ;
BIANCHI, FB ;
BIANCHI, L ;
BURROUGHS, A ;
CHAPMAN, RW ;
CZAJA, AJ ;
DESMET, V ;
EDDLESTON, ALWF ;
GERBER, MA ;
HOFFNAGLE, JH ;
KAKUMU, S ;
MACSWEEN, RNM ;
MADDREY, WC ;
MANNS, MP ;
ZUMBUSCHENFELDE, KHM ;
MIELIVERGANI, G ;
PORTMANN, BC ;
REED, WD ;
SCHALM, SW ;
SCHEUER, PJ ;
TODA, G ;
TSUJI, T ;
TYGSTRUP, N ;
VERGANI, D ;
ZENIYA, M .
HEPATOLOGY, 1993, 18 (04) :998-1005
[8]   MEDICAL APPROACHES TO PRIMARY SCLEROSING CHOLANGITIS [J].
KAPLAN, MM .
SEMINARS IN LIVER DISEASE, 1991, 11 (01) :56-63
[9]  
KLATSKIN G, 1993, HISTOPATHOLOGY LIVER, V1, P68
[10]  
KRAWITT EL, 1991, AUTOIMMUNE LIVER DIS, P63